Open Access
CC BY 4.0 · Arch Plast Surg 2024; 51(04): 372-377
DOI: 10.1055/a-2306-0962
Pediatric/Craniomaxillofacial/Head & Neck
Idea and Innovation

A Triple Laser Combination Treatment for Facial Angiofibromata Management in Tuberous Sclerosis and Literature Review

F. Neamonitou 
1   Department of Plastic Surgery, General Anticancer Oncological Hospital of Athens ‘Saint Savvas’, Athens, Greece
,
K.K. Neamonitos 
2   Department of Dermatology, General University Hospital of Athens ‘Attikon’, Athens, Greece
,
S. Stavrianos 
1   Department of Plastic Surgery, General Anticancer Oncological Hospital of Athens ‘Saint Savvas’, Athens, Greece
,
K.P. Neamonitos 
3   Hellenic Society of Dermatology Surgery (HSDS), Private Dermatological Clinic ‘Laserderm Academy’, Athens, Greece
› Author Affiliations
Funding None.
› Further Information
  Permissions and Reprints
Preview

Abstract

Angiofibromas are a common facial manifestation of tuberous sclerosis (TS). However, current treatments have proven ineffective due to high recurrence rates and noncompliance. To address this issue, we developed a new triple laser therapy protocol for more effective management of angiofibromas. We conducted tests to validate its efficacy. This is a prospective study of 10 patients with TS (4 women and 6 men, mean age 26.3 years [15–37 years]) with angiofibromata who received triple sequential laser therapy at our private dermatological clinic conducted from January 2000 to December 2022. We evaluated the outcome with the Facial Angiofibromata Severity Index (FASI) via clinical photography (0, 6 months, 1 year, and 2 years), and Dermatology Life Quality Index (DLQI). All patients had a successful recovery without any complications. Among these 10 patients, 4 experienced localized recurrences at their 6-month follow-up. These recurrences were treated with a second single carbon dioxide laser session. After 2 years of follow-up, we observed no recurring facial cutaneous manifestations. Furthermore, all patients experienced a decrease in their FASI score after treatment. According to the Visual Analogue Scale, patients reported 95% satisfaction, and DLQI indicated only a minor impact on their everyday lives. We believe that this protocol of three-step laser treatment is effective, safe, and compliable for patients with facial angiofibromata, providing a satisfactory outcome adaptable to the daily dermatological and plastic surgery practice.

Keywords

angiofibroma - Erbium - laser - pulsed dye laser - tuberous sclerosis

Authors' Contributions

Conceptualization: F.N., K.P.N., Data curation: F.N., K.K.N. Formal analysis: F.N., K.K.N. Methodology: F.N. Project administration: K.P.N. Writing - original draft: F.N., K.K.N. Writing - review & editing: F.N., K.P.N., S.S.


Ethical Approval

The study was approved by the Institutional Review Board of the Dermatological Clinic Laserderm Academy and performed in accordance with the principles of the Declaration of Helsinki. Written informed consents were obtained.


Patient Consent

Before treatment, we obtained informed consent from all patients or their guardians in case the patients could not obtain consent.




Publication History

Received: 20 July 2023

Accepted: 09 April 2024

Accepted Manuscript online:
15 April 2024

Article published online:
14 June 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA